Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

Next Previous
X
Search
Trial Profile

A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Abacavir; Antiretrovirals; Didanosine; Efavirenz; Emtricitabine; Lamivudine; Stavudine; Zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms HIV
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 11 Mar 2020 Results (n=247) assessing relative contribution of antiretroviral therapy (ART) and alterations in the renal-bone axis to lower bone mineral density, presented at the 27th Conference on Retroviruses and Opportunistic Infections.
    • 07 Mar 2019 Results presented at the 26th Conference on Retroviruses and Opportunistic Infections
    • 30 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top